ArticleJournal of orthopaedic case reports2025
Role of Biomarkers in Diabetic Foot Osteomyelitis.
Article in Journal of orthopaedic case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From serum inflammatory markers to fluid, tissue, and molecular assays: current advances in the laboratory diagnosis of bone and joint infections.Frontiers in cellular and infection microbiology · 2026Review
- Early postoperative C-reactive protein-to-albumin ratio for risk stratification of osteomyelitis recurrence after surgical treatment.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Foot ulcer is one of the common problems in patients with diabetes mellitus. The spectrum of diabetic foot infection is wide, ranging from cellulitis and soft tissue infection to osteomyelitis (OM). OM requires further testing and investigations and even longer treatments. The aim of this prospective study was to assess the performance of serum markers, namely, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and procalcitonin (PCT) in the diagnosis and follow-up of patients with diabetic foot osteomyelitis (DFO) and to find correlation between serum levels of these biomarkers and treatment response. Materials and Methods: This prospective study was carried out in 50 patients. Diagnosis of OM was made by clinical examination and confirmed by radiological studies. The serum levels of ESR, CRP, and PCT were determined on admission in all the patients and then on day 15 and day 30 in the osteomyelitic group. Results: No significant difference was observed in the levels of ESR, CRP, and PCT in DFO and non-OM patients (P > 0.05) at presentation. However, there was a significant difference (P > 0.05) in levels of these markers between patients with healed and non-healed lesions in the osteomyelitic group on day 15 and day 30. Conclusion: Biomarkers may not help in diagnosing OM. However, the level of biomarkers decreases significantly in response to treatment validating their role in predicting healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.